ArticleFrontline gastroenterology2015
Burden of irritable bowel syndrome in an increasingly cost-aware National Health Service.
Article in Frontline gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03806959 (Interest of Pan Capsule), which is not on this map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Interest of Pan Capsule (Small Bowel and Colon Video Capsule) in Symptomatic Patients Suspected of Irritable Bowel Syndrome Requiring Colonoscopy Phase A Feasibility
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Cost-of-Illness of Irritable Bowel Syndrome: A Systematic Review.Journal of gastroenterology and hepatology · 2026Pooled it
- Exploring IBS in Vietnam: an updated review of current trends and treatment landscape.Frontiers in medicine · 2026Pooled it
- Vitamin D status in irritable bowel syndrome and the impact of supplementation on symptoms: what do we know and what do we need to know?European journal of clinical nutrition · 2018Pooled it
- Vitamin D supplementation in people with IBS has no effect on symptom severity and quality of life: results of a randomised controlled trial.European journal of nutrition · 2022Trial
- Return on investment of internet delivered exposure therapy for irritable bowel syndrome: a randomized controlled trial.BMC gastroenterology · 2021Trial
- A 5Ad Dietary Protocol for Functional Bowel Disorders.Nutrients · 2019Trial
- Article
- Racial Disparities in the Diagnosis and Management Between Secondary Care Ethnic Minority and White British Patients With Irritable Bowel Syndrome.Neurogastroenterology and motility · 2026Article
- Economic impact of steroid-induced comorbidities in severe asthma: a SHARP CRC simulation.ERJ open research · 2025Article
- Disorders of Gut-Brain Interaction in a Pediatric Cystic Fibrosis Cohort.Pediatric pulmonology · 2025Observational
- Panenteric Capsule Endoscopy in Young Patients with Suspected Irritable Bowel Syndrome: A Self-Controlled Feasibility Study.Clinical and experimental gastroenterology · 2025Article
- Mast cell modulation: A novel therapeutic strategy for abdominal pain in irritable bowel syndrome.Cell reports. Medicine · 2024Review
- Development and validation of a knowledge, attitudes and practices questionnaire in the dietary management of irritable bowel syndrome.European journal of clinical nutrition · 2023Article
- Article
- Article
- Is Irritable Bowel Syndrome out of date and misleading as a diagnosis?Gastroenterology and hepatology from bed to bench · 2023Article
- Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.Alimentary pharmacology & therapeutics · 2022Article
- Irritable bowel syndrome in Egyptian medical students, prevalence and associated factors: a cross-sectional study.The Pan African medical journal · 2022Article
- Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders.Nature genetics · 2021Article
- Tetrodotoxin: A New Strategy to Treat Visceral Pain?Toxins · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe National Health Service (NHS) is faced with increasing cost pressures that make the efficient use of resources paramount. Irritable bowel syndrome (IBS) places a large burden on the NHS as it has been estimated that at least 12% of the UK population is affected. However, poor clinical coding makes accurate assessment of this burden challenging.
objectiveTo calculate primary-care prescribing and both hospital outpatient and admission costs associated with the management of IBS in England. DESIGN AND
main outcome measuresHospital Episode Statistics data for 2012-2013 for all clinical commissioning groups in England were analysed to calculate the tariff cost of IBS. Prescribing analysis and cost tabulation (PACT) data for this period were also analysed.
resultsIn 2012-2013, there were 1 219 961 outpatient attendances in gastroenterology and colorectal surgery specialties. Despite this, only 1982 patients were recorded with IBS-specific codes, with a total estimated tariff cost of £812 336. In addition, 28 849 patients were recorded with IBS-related symptom codes at a cost of £11 002 874. In 2011-2012, there were 658 698 diagnostic lower gastrointestinal endoscopies at a tariff cost of £16 967 670 4. Of these, 323 752 (49%) had no further follow-up in secondary care over the subsequent 12 months. PACT data indicated that £44 977 959 and £25 582 752, respectively, were spent on selected laxatives and antispasmodics commonly used to treat IBS in primary care.
conclusionsBetter diagnosing, through improved clinical coding and standardisation of diagnostic criteria, is required to more accurately assess the true burden and allow optimal management of IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.